Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Ipca Laboratories is currently trading at Rs. 668.80, up by 16.05 points or 2.46% from its previous closing of Rs. 652.75 on the BSE.
The scrip opened at Rs. 664.05 and has touched a high and low of Rs. 675.65 and Rs. 663.50 respectively. So far 26184 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 899.30 on 30-Jun-2014 and a 52 week low of Rs. 591.25 on 09-Feb-2015.
Last one week high and low of the scrip stood at Rs. 677.20 and Rs. 651.20 respectively. The current market cap of the company is Rs. 8486.92 crore.
The promoters holding in the company stood at 45.89% while Institutions and Non-Institutions held 33.04% and 21.07% respectively.
Reserve Bank of India (RBI) has allowed Ipca Laboratories to raise its foreign investment limit up to 35% of paid-up capital. RBI has notified that Foreign Institutional Investors (FIIs)/Registered Foreign Portfolios Investors (RFPIs) can now invest up to 35% of the paid up capital of Ipca Laboratories under the Portfolio Investment Scheme (PIS). The company has passed resolutions at its Board of Directors’ level and a special resolution by the shareholders, agreeing for enhancing the limit for the purchase of its equity shares and convertible debentures by FIIs/RFPIs.
RBI has further notified that the foreign shareholding by FIIs/RFPIs in Ipca Laboratories has gone below the revised threshold caution limit. Hence the restrictions placed on the purchase of shares of the above company are withdrawn with immediate effect.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1515.00 |
| Dr. Reddys Lab | 6339.05 |
| Cipla | 1425.00 |
| Zydus Lifesciences | 996.05 |
| Lupin | 1656.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
